Quidel Corporation (QDEL)

Check out top investors' recommendation for QDEL
Last closing price (Mar 04 4:00 EDT):
25.95 (0.54%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
4.01% ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women’s health, and gastrointestinal diseases. The company’s products for infectious diseases include QuickVue influenza test to detect viral antigens of influenza type A and B; QuickVue Strep A tests to detect Group A Streptococcal antigen from throat swabs or confirmation of presumptive Group A Streptococcal colonies recovered from culture; QuickVue RSV test, a rapid immunoassay for respiratory syncitial virus; and cell culture and DFA detection solutions to detect seven viral respiratory pathogens. It also offers cell-based products in various formats, including tubes, shell vials, and multi-well plates to culture and test for human viruses; ELVIS HSV system for the isolation and detection of herpes simplex virus (HSV) types 1 and 2; and a multiplex cell culture solution to isolate HSV, varicella zoster virus, and cytomegalovirus, as well as provides various analyzers and molecular assays. The company’s products for women’s health consist of QuickVue and RapidVue pregnancy tests to detect human chorionic gonoadotropin in serum or urine for the early detection of pregnancy; Thyretain for the diagnosis of graves, an autoimmune disease; QuickVue Chlamydia test to detect chlamydia trachomatis from endocervical swab and cytology brush specimens; and clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation, including metabolic bone markers to monitor the effectiveness of therapy in pharmaceutical and related research. In addition, it provides a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; and Helicobacter pylori tests, as well as develops diagnostic and research products in the fields of oncology, bone health, and autoimmune diseases. The company was founded in 1979 and is headquartered in San Diego, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Brian Weinstein William Blair & Company, L.L.C. Buy   Dec 18, '14   27.49    Dec 18, '15  -5.60% 
Nicholas Jansen Raymond James Buy   Jul 23, '14   25.33  26.00  Jul 23, '15  2.65% 
Jeffrey Frelick Canaccord Genuity Buy   Jul 23, '14   25.33  26.00  Jul 23, '15  2.65% 
Jeffrey Frelick Canaccord Genuity Buy   Apr 24, '14   21.55  28.00  Apr 24, '15  29.93% 
Zarak Khurshid Wedbush Securities Inc. Sell   Aug 02, '13   26.50  18.00  Aug 02, '14  10.11% 
Jeffrey Frelick Canaccord Genuity Buy   Jul 31, '13   26.77  35.00  Jul 31, '14  -10.16% 
Jeffrey Frelick Canaccord Genuity Buy   Mar 07, '13   24.33  30.00  Mar 07, '14  23.30% 
Zarak Khurshid Wedbush Securities Inc. Sell   Mar 03, '13   24.14  16.00  Mar 03, '14  -16.07% 
Nicholas Jansen Raymond James Buy   Jan 01, '13   19.87  22.00  Jan 01, '14  55.46% 
Jeffrey Frelick Canaccord Genuity Buy   Jul 26, '12   15.91    Jul 26, '13  83.47%